Beth Seidenberg

Beth Seidenberg
Name	Beth Seidenberg
Education	University of Michigan (BS), University of Miami (MD)
Occupation	Venture capitalist, physician
Known for	Life sciences venture capital
Boards	Gilead Sciences, Denali Therapeutics, Guardant Health, Intarcia Therapeutics

Beth Seidenberg is an American physician and venture capitalist specializing in the life sciences and biotechnology sectors. She is a founding managing director of Westlake Village BioPartners and was previously a general partner at the prominent venture capital firm Kleiner Perkins. Seidenberg is recognized for her work in building and investing in numerous innovative healthcare companies, serving on the boards of several leading public and private firms in the industry.

Early life and education

Seidenberg earned a Bachelor of Science degree from the University of Michigan. She then pursued her medical degree at the University of Miami Leonard M. Miller School of Medicine, followed by a residency in internal medicine at NewYork-Presbyterian Hospital. She completed a fellowship in rheumatology and immunology at the Hospital for Special Surgery and conducted research at the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Career

Before entering venture capital, Seidenberg held significant roles in the pharmaceutical and biotechnology industry. She served as the chief medical officer and senior vice president of development at Amgen, where she oversaw clinical development. Earlier in her career, she held various positions in clinical research and development at Bristol-Myers Squibb and worked as a staff fellow at the Food and Drug Administration. Her operational experience spans the entire drug development process from discovery through commercialization.

Kleiner Perkins and venture capital

In 2005, Seidenberg joined Kleiner Perkins as a partner, focusing on investments in life sciences. During her tenure, she led investments in and served on the boards of numerous successful companies, playing a key role in the firm's healthcare portfolio. Notable investments from this period include Atara Biotherapeutics, Flexus Biosciences (acquired by Bristol-Myers Squibb), and Juno Therapeutics (acquired by Celgene). Her work at Kleiner Perkins established her as a leading investor in cell therapy, oncology, and immunology.

Westlake Village BioPartners

In 2018, Seidenberg co-founded Westlake Village BioPartners with fellow Kleiner Perkins partner Sean Harper. The firm, based in Los Angeles, focuses on creating and investing in next-generation biotechnology companies. Under her leadership, Westlake Village BioPartners has founded and funded companies such as Korro Bio, Nurix Therapeutics, and Triumvira Immunologics. The firm aims to leverage deep scientific expertise to advance novel therapeutics for serious diseases.

Board memberships and affiliations

Seidenberg holds board positions at several prominent public and private healthcare companies. She serves on the board of directors for Gilead Sciences, Denali Therapeutics, and Guardant Health. She is also chairman of the board for Intarcia Therapeutics and serves on the boards of private companies like Nurix Therapeutics and Triumvira Immunologics. Additionally, she is a member of the board of trustees for the University of Miami and the California Institute of Technology.

Personal life

Seidenberg is married to Tom Seidenberg, an attorney. She maintains an active role in mentoring entrepreneurs and advocating for women in science and venture capital. Her contributions to biotechnology have been recognized by awards such as the University of Miami’s Distinguished Alumni Award.

Category:American venture capitalists Category:American physicians Category:21st-century American businesspeople